Vorlage:Mdy Vorlage:Drugbox Lansoprazole (Vorlage:IPA-en, lan-SOE-pra-zole, INN) is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol). It was first approved by the U.S. Food and Drug Administration (FDA) in 1995.^[1]

Prevacid patent protection expired on November 10, 2009.^[2][3] As a result, prescription Lansoprazole is now available in the form of a generic drug. Vorlage:As of lansoprazole is available over-the-counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.^[4][5][6]

Currently (November 25, 2009), prescription Lansoprazole and OTC Prevacid sell for about 50% and 25% of the cost of prescription Prevacid, respectively, in the U.S.

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.^[7] Lansoprazole is a racemate [1:1-mixture of the enantiomers dexlansoprazole (Kapidex) and levolansoprazole].^[8] Dexlanprantazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,^[9] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.^[10]

Vorlage:Unreferenced section Lansoprazole is indicated for:

• Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers
• Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)
• Treatment of Zollinger-Ellison Syndrome
• Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics

• PPIs reduce absorption of antifungals (itraconazole and ketoconazole) ^[11]and possibly increase Digoxin in plasma
• Increases plasma concentrations of Cilostazol (risk of toxicity)
• Absorption of lansoprazole possibly reduced by:
  • sucralfate
  • ampicillin
  • bisacodyl
  • delavirdine
  • fluvoxamine
  • iron salts
  • theophylline
  • voriconazole
  • aminophylline and theophylline
  • astemizole

Vorlage:Refimprove

• Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
• Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions (including erythroderma,^[12] Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
• Severe: Gastro-intestinal disturbances (such as nausea 1.3%, abdominal pain 2.1%, diarrhea 3.8%).^[9]

Proton-pump inhibitors may be associated with a greater risk of hip fractures,^[13] clostridium difficile-associated diarrhea.^[14] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.^[15]

The drug is sold under several brand names, including:^[1]

• Agopton (Germany)
• Lansor (Turkey)
• Digest (Indonesia)
• Duogast (Syria)
• Gastrolan (Indonesia)
• Lanpro (India)
• Lanzol (India)
• Lanzul (Slovenia)
• Lansoptol (Hungary)
• Lansox (Italy)
• Lansoloc (South Africa)
• Lanston LFDT (South Korea)
• Lanton (Israel)
• Lanzo (Sweden)
• Lanzor (France, South Africa)
• Lanzostad (Lithuania, Latvia, Estonia)
• Laprazol (Greece)
• Lanciprol (Greece)
• Limpidex (Italy)
• Monolitum (Spain)
• Ogast and OgastORO (France)
• Ogastro (Mexico)
• Prevacid (U.S. and Canada) Prevacid is a product of Takeda Pharmaceuticals.
• Prevacid 24HR (U.S.)
• pro-ulco (Spain)
• Prosogan and Prosogan FD (Indonesia)
• Refluxon (Hungary)
• SOLOX (New Zealand)
• Takepron (Japan)
• Zolt (Finland)
• Zoton (Italy, Ireland, Australia, UK)
• ZOMEL (Ireland)

Lansoprazole is also available as a generic drug in the US, UK, Canada, Belgium, Finland,^[16] France, Colombia, Italy, Sweden,^[17] and Mexico.Vorlage:Citation needed

Vorlage:Reflist

• Prevacid official website Takeda Pharmaceuticals North America
• Prevacid 24HR official website Novartis Consumer Health
• Prevpac official website Takeda Pharmaceuticals North America
• U.S. National Library of Medicine: Drug Information Portal - Lansoprazole

Vorlage:Proton-Pump Inhibitors

1. ↑ ^{a b} Mosby's Drug Consult: Lansoprazole
2. ↑ Prevacid drug patents
3. ↑ Teva to release Prevacid version when patent expires
4. ↑ Vorlage:Cite press release
5. ↑ Prevacid 24HR Patient Package Insert. (PDF) 12. November 2009, abgerufen am 13. November 2009. 
6. ↑ Vorlage:Cite press release
7. ↑ http://www.patient.co.uk/showdoc/30002943/
8. ↑ http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf
9. ↑ ^{a b} Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism. RxList.com, 2007, abgerufen am 14. April 2007.  Referenzfehler: Ungültiges <ref>-Tag. Der Name „RxList“ wurde mehrere Male mit einem unterschiedlichen Inhalt definiert.
10. ↑ Prevacid 24HR Fact Sheet. (PDF) 12. November 2009, abgerufen am 13. November 2009. 
11. ↑ Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]
12. ↑ Sterry W, Assaf C: Dermatology. Hrsg.: Bolognia JL. Mosby, St. Louis 2007, ISBN 1-4160-2999-0, Erythroderma, S. 154. 
13. ↑ Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. In: JAMA. 296. Jahrgang, Nr. 24, Dezember 2006, S. 2947–53, doi:10.1001/jama.296.24.2947, PMID 17190895.  Fehler beim Aufruf der Vorlage:Cite journal: Der Parameter 'format', 'access-date' (bzw. Alias) oder 'archive-url' (bzw. Alias) wurde angegeben, aber der Parameter 'url' fehlt.
14. ↑ Proton pump inhibitors and Clostridium difficile. Bandolier, 2003, abgerufen am 13. Juli 2007. 
15. ↑ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER: Acid-suppressive medication use and the risk for hospital-acquired pneumonia. In: JAMA. 301. Jahrgang, Nr. 20, Mai 2009, S. 2120–8, doi:10.1001/jama.2009.722, PMID 19470989.  Fehler beim Aufruf der Vorlage:Cite journal: Der Parameter 'format', 'access-date' (bzw. Alias) oder 'archive-url' (bzw. Alias) wurde angegeben, aber der Parameter 'url' fehlt.
16. ↑ Vastaavat tuotteet - hintavertailu. Abgerufen im 1. Januar 1 (finnisch). 
17. ↑ FASS.se, accessed 2010-02-13. Abgerufen im 1. Januar 1 (schwedisch).